The outcome of Autologous Stem Cell Transplantation in First Complete Remission Acute Myeloid Leukemia Patients- Single Center Study
Post-remission treatment in patients with acute myeloid leukemia is still controversial. One potent choice for patients with no donor available is autologous stem cell transplantation. The median follow-up period was 18 months and the median age was 26 years old. In the review of 116 recently diagno...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2011-10-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/20841.pdf&manuscript_id=20841 |
| Summary: | Post-remission treatment in patients with acute myeloid leukemia is still controversial. One potent choice for patients with no donor available is autologous stem cell transplantation. The median follow-up period was 18 months and the median age was 26 years old. In the review of 116 recently diagnosed AML patients (except AML- M3) who underwent autologous stem cell transplantation, 72.4% of patients remained alive and 27.6% relapsed. Relapse was the most common causes of death in patients. The one- year OS and DFS of patients was 73.8% and 59.8%, respectively. There was no statistically significant difference between age, sexuality and waiting time from diagnosis to transplantation. For more comprehensive results, longer follow- up is required. |
|---|---|
| ISSN: | 2008-3009 2008-2207 |